VytlOne Partners with Insmed to Distribute Brinsupri for Non-Cystic Fibrosis Bronchiectasis Treatment.

VytlOne, a company with a subsidiary Maxor Specialty Pharmacy, has partnered with Insmed to distribute Brinsupri, a medication for non-cystic fibrosis bronchiectasis. This marks the latest addition to VytlOne's limited distribution products. VytlOne's President, Joel Wright, expressed excitement about the partnership, highlighting the company's commitment to the rare disease community and its mission to improve patient outcomes. The partnership underscores VytlOne's focus on rare and orphan disease management.

VytlOne, a leading provider of total pharmacy solutions, has announced a new partnership with Insmed to distribute Brinsupri, a medication for non-cystic fibrosis bronchiectasis (NCFB). This collaboration marks the latest addition to VytlOne's growing portfolio of limited distribution products. The partnership underscores VytlOne's commitment to the rare disease community and its mission to improve patient outcomes.

Brinsupri, a dipeptidyl peptidase 1 (DPP1) inhibitor, was recently approved by the FDA as the first and only treatment for NCFB. The medication is designed to inhibit the activation of enzymes in neutrophils that are key drivers of chronic airway inflammation in NCFB. The approval represents a significant advancement for patients and clinicians managing this chronic and progressive lung disease, which affects approximately 500,000 people in the U.S. and millions globally.

Joel Wright, President of VytlOne Pharmacy Services, expressed excitement about the partnership, stating, "We are excited to partner with Insmed for the launch of Brinsupri, the first FDA-approved medication for the treatment of bronchiectasis. This milestone underscores our commitment to the rare disease community, and we are honored to play a role in the improvement of the lives of our bronchiectasis patients" [1].

The partnership aligns with VytlOne's strategy to integrate sophisticated clinical management strategies with a personalized, high-touch approach to patient engagement. With licenses in all 50 states and accreditations from URAC, ACHC, and The Joint Commission, VytlOne supports and enables its partners to drive sustainable revenue growth while achieving optimal outcomes for patients living with rare diseases.

Insmed, a people-first global biopharmaceutical company, is dedicated to delivering first- and best-in-class therapies to transform the lives of patients facing serious diseases. The FDA approval of Brinsupri marks a historic milestone for patients and for Insmed, which is committed to providing access to its products through various financial assistance options and patient support programs.

The partnership between VytlOne and Insmed is expected to enhance the availability and accessibility of Brinsupri, benefiting patients with NCFB across the U.S. Commercial launches are anticipated in 2026, pending approval in each territory.

References:
[1] VytlOne. (2025, Aug. 13). VytlOne Announces New Partnership with Insmed. PRNewswire. Retrieved from https://www.prnewswire.com/news-releases/vytlone-announces-new-partnership-with-insmed-302529214.html
[2] Insmed. (2025, Aug. 12). FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis. PRNewswire. Retrieved from https://investor.insmed.com/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease